Study Summary
This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors.
Interested in this trial?
Submit an InquiryInterventions
Anti-HER2 CAR-T cellsBIOLOGICAL
All eligible participants will receive a conditioning chemotherapy regimen of fludarabine, cyclophosphamide and ABRAXANE followed by Anti-HER2 CAR-T cell injection.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | China |